The French pharmaceutical group Servier has transferred the technology to manufacture original brand medicines to Ampharco U.S.A Vietnam, with products expected to launch by the end of 2026.
The signing ceremony, held on May 27 under the witness of government representatives from both Vietnam and France, formalized the agreement. Servier will transfer the technology for five medicines used in the treatment of common conditions such as diabetes, cardiovascular diseases, and venous insufficiency.
Ampharco’s manufacturing plant in Nhon Trach Industrial Park, Dong Nai Province, will produce around 50% of the medicines distributed in Vietnam. The company will operate the entire process under the supervision of Servier’s technical team, ensuring that locally produced medicines meet the same quality standards as those manufactured in Europe.
Signing Ceremony between Servier and Ampharco U.S.A. Photo: Ampharco U.S.A
According to Mr. Serge Nicollerat, General Director of Servier Vietnam, the decision to transfer technology was based on three key factors: Vietnam’s market potential, stable healthcare policies, and strong local manufacturing capacity. Ampharco possesses a fully integrated pharmaceutical ecosystem covering research, manufacturing, distribution, and marketing, along with an EU-GMP-certified plant—a critical requirement for receiving the technology transfer of original brand medicine production.
Ampharco representatives emphasized that the collaboration marks an important milestone, confirming Vietnam’s reliability and capability to receive advanced pharmaceutical technology. Local production of original brand medicines will help reduce dependence on imports and provide patients with access to high-quality treatments at reasonable costs.
Ampharco U.S.A’s Manufacturing Plant. Photo: Ampharco U.S.A
Original brand medicines are the first drugs to be licensed for circulation based on comprehensive data on quality, safety, and efficacy. They are exclusive, high-value products requiring significant investment in R&D and subject to strict protection, making technology transfer rare.
According to Vietnam’s National Pharmaceutical Development Strategy to 2030, with a vision to 2045, the country aims to locally produce at least 80% of medicines consumed domestically, including 100 original brand drugs through technology transfer. However, such transfers remain limited due to technical barriers and intellectual property protection.
Servier has been active in Vietnam for over 30 years, serving more than three million patients annually. Founded in 1969, Ampharco U.S.A has grown into a diversified pharmaceutical company engaged in the production of medicines and dietary supplements, as well as research and development, contract manufacturing, and export.
Source:
https://vnexpress.net/ampharco-duoc-chuyen-giao-cong-nghe-san-xuat-biet-duoc-goc-4896911.html